Emergent BioSolutions (EBS) Invested Capital (2010 - 2026)

Emergent BioSolutions' Invested Capital history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Invested Capital fell 11.17% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (down 11.17% YoY), while the FY2025 annual figure was $1.1 billion, down 5.96% from the prior year.
• Invested Capital was $1.1 billion for Q1 2026 at Emergent BioSolutions, roughly flat from $1.1 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $2.8 billion in Q4 2022 to a low of $1.1 billion in Q4 2025.
• Historically, Invested Capital has averaged $1.7 billion across 5 years, with a median of $1.5 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Invested Capital increased 13.83% in 2022, then sank 45.83% in 2023.
• A 5-year view of Invested Capital shows it stood at $2.8 billion in 2022, then tumbled by 45.83% to $1.5 billion in 2023, then dropped by 22.07% to $1.2 billion in 2024, then declined by 5.96% to $1.1 billion in 2025, then grew by 0.04% to $1.1 billion in 2026.
• The last three Invested Capital figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.